NEW YORK, Aug. 1, 2016 /PRNewswire/ -- The U.S. Patent & Trademark Office (PTO) granted a petition for inter partes review (IPR) filed by Argentum Pharmaceuticals LLC and its manufacturing partner KVK Tech, against all challenged claims of the sole patent listed as covering Alcon's PAZEO® (0.7% olopatadine hydrochloride ophthalmic solution) drug in the Food & Drug Administration's Orange Book. Argentum and KVK challenged claims 1-4, 8, 12, 13, 21 and 22 of Alcon's U.S. Patent No. 8,791,154, and on July 18, 2016 the PTO concluded there is a "reasonable likelihood that [petitioner] would prevail in showing that the claims it challenges are unpatentable". The decision marks the beginning of an IPR trial that will be conducted by three specialist patent judges within the PTO's Patent Trial & Appeal Board (PTAB). A final decision on patentability in the IPR is due within 1 year. The successful institution of this petition marks the first time the PTAB has instituted an IPR against this patent.
About Argentum Pharmaceuticals
Argentum is a generic drug company with core competencies in intellectual property and pharmaceutical operations. By working with branded and generic pharmaceutical companies and healthcare payors, Argentum intends to reduce the overall cost of prescription drugs by challenging patents that are not innovative and which artificially support high drug prices. www.argentumpharmaceuticals.com
About KVK Tech
KVK is a recognized leader in the development and manufacture of high-quality, FDA-approved medicines, and possesses operational expertise in pharmaceutical manufacturing, packaging, sales, distribution, research & development, and customer service. KVK's expertise runs the gamut and includes solid oral, powder, liquid, and proprietary dosage technologies. KVK has expanded its capabilities into sterile products as well, with a 225,000 sq./ft., state-of-the-art sterile injectable facility being qualified later this year. KVK takes pride in its ability to advance medical care and offer low-cost, high-quality alternatives in response to today's healthcare challenges. KVK is one of the few manufacturers of generic pharmaceuticals who handles all of its manufacturing, packaging, and distribution in the United States. www.kvktech.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/argentum-pharmaceuticals-and-kvk-tech-succeed-in-starting-patent-cancellation-trial-against-alcons-pazeo-300307269.html
SOURCE Argentum Pharmaceuticals